The drugs effects go beyond LDL-lowering in ways that might potentially benefit hospitalized patients with COVID-19, at least those who are sickest, preliminary results suggest.
An increase in the use of two types of antibiotics to treat COVID-19 may have contributed to a rise in antimicrobial-resistant strains of Streptococcus pneumoniae.